Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy.
about
Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesisSystematic review of biomarkers to monitor therapeutic response in leishmaniasisImmunotherapy for visceral leishmaniasis: ability of factors produced during anti-leishmania responses of skin test positive adults to inhibit peripheral blood mononuclear cell activities associated with visceral leishmaniasisRole of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replicationPathogenesis of chagas' disease: parasite persistence and autoimmunityQuantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasisEvidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis.Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasisClinical and experimental advances in treatment of visceral leishmaniasis.Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression.Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms.Arginase activity - a marker of disease status in patients with visceral leishmaniasis in ethiopiaCharacterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy.Elevated Serum ADA Activity as a Marker for Diagnosis and Prognosis of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis in Indian Patients.Blood Transcriptional Profiling Reveals Immunological Signatures of Distinct States of Infection of Humans with Leishmania infantum.Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasisBehavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model.Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.Tracing immunity to human leishmaniasis.Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.Natural killer cells in experimental and human leishmaniasis.Kinesin motor domain of Leishmania donovani as a future vaccine candidate.NOD2-RIP2-Mediated Signaling Helps Shape Adaptive Immunity in Visceral Leishmaniasis.Elevated TGF-beta levels in drug-resistant visceral leishmaniasis.Serum soluble markers in the evaluation of treatment in human visceral leishmaniasis.Alteration of Fas and Fas ligand expression during human visceral leishmaniasis.Altered serum cytokine and immunoglobulin levels in the workers exposed to antimony.Decrease in the Frequency of Circulating CD56+CD161+ NK Cells in Human Visceral Leishmaniasis.Monocyte-Derived Signals Activate Human Natural Killer Cells in Response to Leishmania Parasites.Ribavirin up-regulates IL-12 p40 gene expression and restores IL-12 levels in Leishmania-treated PBMCs.
P2860
Q25256772-1AB10121-D2A8-4265-BE42-2EC1C345370CQ26866450-A0B4CEE2-326C-4871-9E1B-0BB30E35F54AQ28137699-3DC26BBB-7A80-4F18-8D28-019014EF2509Q28343594-32F49DEC-E962-46A9-8088-78D5C9831263Q28742827-3B4C1455-EC1E-47D2-B557-338075CBA0A5Q33559747-11BFED5E-8C98-45A5-BDC3-BF37662588FBQ33963990-D90C513C-50A4-4F44-A122-12ED616958A1Q33979661-0801D7A5-C46F-4C66-827E-4AAC37CA8821Q33982648-5F87FC83-17C1-4430-A46D-E4681A17CBFBQ34139938-2F8F4D8B-C725-4387-8BE3-B13092CD71F5Q34181985-AF49DCC4-DA3C-4DB8-9B83-6A761EF45010Q34284119-F9FED0FD-CE6B-43BE-B220-BF7F22AE98AAQ34654225-2735587B-D772-433D-A348-091CA8DA5F25Q35548955-60EC59EF-D63D-4768-9B8C-47587A51E77DQ36019612-C75F32CB-7F56-408F-BCC3-3B96FA8BDA3EQ36187247-ABEEFCF6-F230-41B9-ABE4-DDF6298C8227Q36229304-9B6249AD-C471-4F17-ACA6-76804BF51B94Q36376855-AD55D678-CF49-46E1-A0C3-99F73999C946Q36845171-0CCD9C4B-E12C-49DE-89E0-6CA736AF98B4Q37405618-9FCBA5F6-37B1-416D-817D-AB512AAAD12FQ37639367-D0544391-4678-4054-B8A8-CDD77C2CE997Q38037557-2472DAA6-7A7E-4A8A-A89F-E61321999BDBQ38606843-A3551BAE-2020-4098-B4CD-847EF69842CFQ39368470-8F90898E-9242-47BE-A5AF-36EA6A93175EQ40774927-D04EF802-EFBD-4643-84EE-421ACF96E566Q40965159-7BFE73BA-E8F3-4213-84B7-4C1DBA5432E8Q43990705-0A80DD1F-D05C-4B5D-8AAC-7F74B8C9E7DBQ45122674-F1491D7A-1239-427C-83F0-350D46D084FBQ48223922-84B17701-A657-410E-825A-5688AEB087DAQ50329879-D093FA15-A084-469B-8B1B-CFBBFDD673D0Q50577648-9047D85E-EF7C-49A9-9399-D271918A081F
P2860
Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Mononuclear cell subpopulation ...... before and after chemotherapy.
@en
Mononuclear cell subpopulation ...... before and after chemotherapy.
@nl
type
label
Mononuclear cell subpopulation ...... before and after chemotherapy.
@en
Mononuclear cell subpopulation ...... before and after chemotherapy.
@nl
prefLabel
Mononuclear cell subpopulation ...... before and after chemotherapy.
@en
Mononuclear cell subpopulation ...... before and after chemotherapy.
@nl
P2093
P356
P1476
Mononuclear cell subpopulation ...... before and after chemotherapy.
@en
P2093
P304
P356
10.1093/INFDIS/168.4.986
P407
P577
1993-10-01T00:00:00Z